Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|November 26, 2013

Coldstream Laboratories Names Head of Formulation Development

Author(s)Melanie Sena

Coldstream Laboratories names director of formulation development.

Coldstream Laboratories, a provider of sterile drug product development and manufacturing services, has named Adrian Raiche, PhD, as director of formulation development. In this position, Raiche will head the formulation development group at Coldstream and will oversee teams focusing on process and product development, lyophilization, and scale-up activities for manufacturing in the company’s sterile manufacturing facility.

Raiche has experience in several aspects of pharmaceutical development, including lyophilization and potent compound handling.  Most recently, he served as manager of pharmaceutical development at Summit Biosciences contributing to formulation, analytical, and process development of nasal-spray products.  Prior experience includes tenures at SiO2 Medical Products, Brookwood Pharmaceuticals, and Bausch and Lomb. 


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.